Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-12-22 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
2022年股权激励计划部分股票期权注销完成的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the cancellation of part of the stock options under the company's 2022 equity incentive plan. It details the number of stock options cancelled, the reasons for cancellation, and confirms compliance with regulatory guidelines. It does not contain financial statements or detailed financial analysis but is a formal disclosure about changes in the equity incentive plan. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about stock option cancellations and does not qualify as a full financial report or other specific filing types.
2024-12-22 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It contains detailed chapters on company organization, shareholder rights, board structure, management, financial accounting, profit distribution, audit, and other governance matters. The content is legal and regulatory in nature, focusing on the internal rules and governance framework of the company rather than financial results, audit opinions, or meeting announcements. It is a comprehensive governance document, not a report of financial performance or an announcement. Therefore, the document best fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2024-12-08 Chinese
2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from the 2024 third extraordinary shareholders' meeting of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, agenda items, voting results, and legal opinions on the meeting's validity. The content focuses on the announcement of voting results for shareholder proposals and governance changes, rather than the meeting materials or the full report itself. The document length is short (1890 characters) and it primarily reports the voting outcomes and legal validation of the meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-12-08 Chinese
北京浩天律师事务所关于北京三元基因药业股份有限公司2024年第三次临时股东大会之法律意见书
Regulatory Filings
2024-12-08 Chinese
持股5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, method, period, and reasons. It also includes compliance statements and risk warnings related to the share reduction. This type of document is a notification about a major shareholding change, specifically a reduction by a significant shareholder. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming the classification with high confidence.
2024-11-28 Chinese
关于全资子公司取得换发后的《药品经营许可证》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining a renewed Drug Business License. It includes details about the license, its validity, and the impact on the company. The document is short (782 characters) and serves as an official notice about a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial data, audit information, or meeting materials. It is an official regulatory announcement about a license renewal, fitting best under Regulatory Filings (RNS).
2024-11-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.